Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Comparison of A New Technique of Measure of the Insulin Resistance By Scintigraphy With the Reference Technique (GLUCIMAG2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02102737
Recruitment Status : Unknown
Verified December 2016 by Institut National de la Santé Et de la Recherche Médicale, France.
Recruitment status was:  Recruiting
First Posted : April 3, 2014
Last Update Posted : December 9, 2016
Sponsor:
Information provided by (Responsible Party):
Institut National de la Santé Et de la Recherche Médicale, France

Brief Summary:

Insulin resistance is closely associated with apparition of type 2 diabetes mellitus; it is an independent risk factor and predicts future cardiovascular events.

Hyperinsulinemic euglycemic clamp is a validated method to assessment of insulin resistance and It is also the gold standard technique. However, the complexity and length of this technique render it unsuitable for routine clinical use.

In this study, the investigators use a new technique to provide precise, objective, fast and automated quantification of insulin resistance with camera SPECT.

They compare the results with those of the measurement of hyperinsulinemic euglycemic clamp in population with or without insulin resistance.

The proposed study is to validate this new non-invasive imaging technique for evaluation of insulin resistance in patients with or without insulin resistance with a comparison with hyperinsulinemic euglycemic clamp.


Condition or disease Intervention/treatment Phase
Diabetes Mellitus Insulin Resistance Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases Drug: 6-DIG Procedure: clamp Phase 2

Detailed Description:

Currently, type II diabetes mellitus, has reached epidemic levels in the world. Moreover, the prediction for the year 2030 is even more alarming. Insulin resistance, characterized by a depressed cellular sensitivity to insulin in insulin-sensitive organs, is a central feature of the metabolic syndrome and a risk factor for type 2 diabetes. Its appearance may precede the diagnosis of true diabetes several years. Insulin resistance results in decreased membrane translocation of GLUT-4, whole the molecular mechanism remains unclear. Currently, there is no simple tool to measure insulin resistance. The gold standard technique remains the hyperinsulinemic euglycemic clamp. However, the complexity and length of this technique render it unsuitable for routine clinical use. Many methods or index have been proposed to assess insulin resistance in human, but none have shown enough relevance to be used in clinical use. Moreover, all these clinical measurements focus on whole-body glucose uptake, however an accurate and convenient procedure for insulin resistance measurement by organ would be interesting. Indeed there are increasingly evidences to insulin resistance as a primary etiologic factor in the development of nonischemic heart failure (HF), another growing public health problem.

Nuclear imaging provides interesting methods to measure insulin resistance using Positron Emission Tomographic (PET) tracer. Two glucose analogs [18F]2-fluoro-2-deoxy-D-glucose (FDG) and [11Cl-30methyl-n-glucose (3-OMG) have been used to evaluate noninvasively the cellular uptake of glucose using PET techniques for several organs like heart, skeletal muscle blood-brain barrier, and liver. [18F] 2-fluoro-2-deoxy-D-glucose (FDG), the most commonly used to study glucose metabolism in humans, allows the estimation of glucose transport and its phosphorylation. A number of kinetic modeling approaches have been used for the quantitation of glucose utilization rates using FDG. FDG is transported and phosphorylated as native glucose, but calculation of glucose uptake and metabolism requires the use of correction factors for each process merged into a lumped constant. The major limitation of these approaches is that quantification of glucose metabolism requires the knowledge of the lumped constant, a factor, which relates the kinetic behavior of FDG to naturally occurring glucose in terms of the relative affinity of each molecule for the trans-sarcolemmal transporter and for hexokinase. Unfortunately, the value of the lumped constant in humans under different physiological and pathophysiological conditions varies, and metabolic imaging with PET need standardization of metabolic conditions by hyperinsulinaemic euglycaemic clamp. 3-OMG appears as an ideal glucose analog to probe transmembrane transport. However, due to the short half-life of the 11C (t1/2 = 20 min), this analog can be used only in clinical institutions in close proximity of a cyclotron and which have access to PET devices.

According to these knowledge, the investigators have developed an original compound, [123I] 6-deoxy-6-iodo-D-glucose (6DIG), as a tracer of glucose transport equivalent to 3-OMG, the reference tracer. 6-DIG has previously been exploited to measure IR in vivo and the investigators transfer to human this measurement technique, perfectly validated in animal. Previous, they have reported the first use a potential single-photon emission computed tomography (SPECT) tracer to study basal and insulin-stimulated glucose transport non-invasively. In a phase I of development, they use a new nuclear probe using an iodinated tracer of glucose transport for clinical application and specific imaging processing to assess cardiac insulinoresistance in healthy or diabetic subjects. The results in human subjects show that this technique rapidly provides insulinoresistance index (ratio scintigraphy measurement of glucose transport in heart before and after infusion of insulin) in a simple procedure, opening up new opportunities for screening for pre-diabetic patients.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Allocation: Non-Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Comparaison d'Une Nouvelle Technique de Mesure de l'insulinorésistance Par Scintigraphie Avec la Technique de référence : Utilisation du 6-DIG Comme Marqueur du Transport du Glucose.
Study Start Date : May 2014
Estimated Primary Completion Date : October 2017
Estimated Study Completion Date : December 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Nuclear Scans

Arm Intervention/treatment
Experimental: 6-DIG and clamp
injection of 6-DIG and hyperinsulinemic euglycemic clamp
Drug: 6-DIG
injection of 6-DIG

Procedure: clamp
hyperinsulinemic euglycemic clamp




Primary Outcome Measures :
  1. Correlation between measure of insulin resistance measurement by scintigraphy and hyperinsulinemic euglycemic clamp [ Time Frame: DAY 1 AND DAY 2 ]
    Correlation between measure of insulin resistance measurement by scintigraphy (insulin resistance index: ratio scintigraphy measurement of glucose transport in heart before and after infusion of insulin) and hyperinsulinemic euglycemic clamp (Glucose Infusion Rate and sensibility index Clamp)


Secondary Outcome Measures :
  1. SAFETY [ Time Frame: visit 2, visit 3 and visit 4 ]
    A systematic collection of adverse events

  2. Reproducibility [ Time Frame: day 2 and day 3 ]
    Reproducibility inter and intra operator of Insulin resistance index

  3. Left ventricule ejection fraction [ Time Frame: day 2 ]
  4. left ventricle volume [ Time Frame: day 2 ]
  5. cardiac mass [ Time Frame: day 2 ]
  6. diastolic function [ Time Frame: day 2 ]
  7. cardiac output [ Time Frame: day 2 ]
  8. pulmonary pressure and right ventricular function [ Time Frame: day 2 ]
  9. strain by speckle tracking echocardiography [ Time Frame: day 2 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Insulin sensible patients

    • Body mass index < 25 HOMA <= 2.5
    • Waist measurement < 94 cm for men and < 80 cm for women
    • HDL cholesterol 1,03 mmol/L for men and > 1,29 mmol/L for women
    • Triglyceride level ≤ 1,69 mmol/ L
    • For women not menopausal since at last one year or not surgically sterilised:

On-going contraception, physical or hormonal, excepted local methods (spermicidal, diaphragm, condom, cape)

- Insulin resistant patients

  • For women not menopausal since at last one year or not surgically sterilised:
  • On-going contraception, physical or hormonal, excepted local methods (spermicidal, diaphragm, condom, cape)
  • HOMA > 2.5
  • Body mass index > 25
  • Waist measurement > 94 cm for men and > 80 cm for women
  • HDL cholesterol < 1,03 mmol/L et for men and ≤ 1,29 mmol/L for women
  • Triglyceride level > 1,69 mmol/ L

Exclusion Criteria:

  • • Instable cardiomyopathy

    • Severe hypertension defined by par SAP > 180 mmHg and/or DAP > 110 mmHg
    • Psychiatric illness, needing a chronic treatment
    • Previous history of stroke, epilepsy, cranial trauma, pituitary surgery, disease likely to reduce the ability of absorption, diffusion or excretion of the radiotracer.
    • Allergy to one of the components of the products used during the study
    • Treatment likely to interfere with glucose metabolism
    • Alcohol or drug intoxication
    • Vegetarian or restrictive low-calory diet,
    • Participation in other biomedical research at the same time or exclusion period under another biomedical research
    • Pregnant, parturient or breast-feeding women,
    • Inappropriate way of life

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02102737


Contacts
Layout table for location contacts
Contact: Gilles Barone-Rochette, PHU 0476768480 GBarone@chu-grenoble.fr

Locations
Layout table for location information
France
Hôpital Michallon . CHU Grenoble Recruiting
Grenoble, France, 38043
Sponsors and Collaborators
Institut National de la Santé Et de la Recherche Médicale, France
Investigators
Layout table for investigator information
Principal Investigator: Gilles Barone-Rochette, PHU Hopital Michalon , CHU de Grenoble
Layout table for additonal information
Responsible Party: Institut National de la Santé Et de la Recherche Médicale, France
ClinicalTrials.gov Identifier: NCT02102737    
Other Study ID Numbers: C13-14
2013-003526-92 ( EudraCT Number )
First Posted: April 3, 2014    Key Record Dates
Last Update Posted: December 9, 2016
Last Verified: December 2016
Keywords provided by Institut National de la Santé Et de la Recherche Médicale, France:
insulin resistance
Scintigraphy
Hyperinsulinemic euglycemic clamp
Additional relevant MeSH terms:
Layout table for MeSH terms
Insulin Resistance
Metabolic Diseases
Glucose Metabolism Disorders
Endocrine System Diseases
Hyperinsulinism